Chronic Rapamycin Treatment Causes Glucose Intolerance and Hyperlipidemia by Upregulating Hepatic Gluconeogenesis and Impairing Lipid Deposition in Adipose Tissue
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The mammalian target of rapamycin (mTOR)/p70 S6 kinase 1 (S6K1) pathway is a critical signaling component in the development of obesity-linked insulin resistance and operates a nutrient-sensing negative feedback loop toward the phosphatidylinositol 3-kinase (PI 3-kinase)/Akt pathway. Whereas acute treatment of insulin target cells with the mTOR complex 1 (mTORC1) inhibitor rapamycin prevents nutrient-induced insulin resistance, the chronic effect of rapamycin on insulin sensitivity and glucose metabolism in vivo remains elusive. RESEARCH DESIGN AND METHODS: To assess the metabolic effects of chronic inhibition of the mTORC1/S6K1 pathway, rats were treated with rapamycin (2 mg/kg/day) or vehicle for 15 days before metabolic phenotyping. RESULTS: Chronic rapamycin treatment reduced adiposity and fat cell number, which was associated with a coordinated downregulation of genes involved in both lipid uptake and output. Rapamycin treatment also promoted insulin resistance, severe glucose intolerance, and increased gluconeogenesis. The latter was associated with elevated expression of hepatic gluconeogenic master genes, PEPCK and G6Pase, and increased expression of the transcriptional coactivator peroxisome proliferator–activated receptor-γ coactivator-1α (PGC-1α) as well as enhanced nuclear recruitment of FoxO1, CRTC2, and CREB. These changes were observed despite normal activation of the insulin receptor substrate/PI 3-kinase/Akt axis in liver of rapamycin-treated rats, as expected from the blockade of the mTORC1/S6K1 negative feedback loop. CONCLUSIONS: These findings unravel a novel mechanism by which mTORC1/S6K1 controls gluconeogenesis through modulation of several key transcriptional factors. The robust induction of the gluconeogenic program in liver of rapamycin-treated rats underlies the development of severe glucose intolerance even in the face of preserved hepatic insulin signaling to Akt and despite a modest reduction in adiposity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Specifically, compensatory pathways are activated in response to chronic rapamycin treatment [66, 67].”
From AMPK hyperactivation promotes dendrite retraction, synaptic loss, and neuronal dysfunction in glaucoma (2021) · cites this paper as [67]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
TOR signaling in growth and metabolism
Wullschleger, S., Loewith, R., & Hall, M. N. (2006) · Cell · doi:10.1016/j.cell.2006.01.016 · Cited by 5,787 · cited 3×
“Diabetes 59:1338–1348, 2010 The mammalian target of rapamycin (mTOR) is a Ser/Thr kinase that belongs to the phosphatidylinositol (PI) kinase-related protein kinase family (1).”
BackgroundWatterson, K. R., Bestow, D., Gallagher, J., Hamilton, D. L., Ashford, F. B., Meakin, P. J., & Ashford, M. L. J. (2013) · Neurosignals · doi:10.1159/000334144 · Cited by 3,389
Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365
Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1
Yoon, J. C., Puigserver, P., Chen, G., Donovan, J., Wu, Z., Rhee, J., Adelmant, G., Stafford, J., Kahn, C. R., Granner, D. K., et al. (2001) · Nature · doi:10.1038/35093050 · Cited by 1,821 · cited 1×
“We also found that rapamycin markedly increases PGC-1 mRNA expression, which likely contributes to the upregulation of the gluconeogenic enzymes, as observed in type 2 diabetes (32).”
BackgroundAbsence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity
Um, S. H., Frigerio, F., Watanabe, M., Picard, F., Joaquin, M., Sticker, M., Fumagalli, S., Allegrini, P. R., Kozma, S. C., Auwerx, J., et al. (2004) · Nature · doi:10.1038/nature02866 · Cited by 1,677
mTOR controls mitochondrial oxidative function through a YY1–PGC-1α transcriptional complex
Cunningham, J. T., Rodgers, J. T., Arlow, D. H., Vazquez, F., Mootha, V. K., & Puigserver, P. (2007) · Nature · doi:10.1038/nature06322 · Cited by 1,488
Insulin-regulated hepatic gluconeogenesis through FOXO1–PGC-1α interaction
Puigserver, P., Rhee, J., Donovan, J., Walkey, C. J., Yoon, J. C., Oriente, F., Kitamura, Y., Altomonte, J., Dong, H., Accili, D., et al. (2003) · Nature · doi:10.1038/nature01667 · Cited by 1,487
CREB regulates hepatic gluconeogenesis through the coactivator PGC-1
Herzig, S., Long, F., Jhala, U. S., Hedrick, S., Quinn, R., Bauer, A., Rudolph, D., Schutz, G., Yoon, C., Puigserver, P., et al. (2001) · Nature · doi:10.1038/35093131 · Cited by 1,440 · cited 1×
“CREB may also promote gluconeogenesis through increased PGC-1 expression (43).”
BackgroundGuertin, D. A., Stevens, D. M., Thoreen, C. C., Burds, A. A., Kalaany, N. Y., Moffat, J., Brown, M., Fitzgerald, K. J., & Sabatini, D. M. (2006) · Developmental Cell · doi:10.1016/j.devcel.2006.10.007 · Cited by 1,415 · cited 1×
“GSK-3 phosphorylation was recently found to be preserved despite complete loss of Akt Ser473 phosphorylation in mouse embryo fibroblasts from rictor knockout animals (49).”
BackgroundPeterson, T. R., Laplante, M., Thoreen, C. C., Sancak, Y., Kang, S. A., Kuehl, W. M., Gray, N. S., & Sabatini, D. M. (2009) · Cell · doi:10.1016/j.cell.2009.03.046 · Cited by 1,202 · cited 1×
“The mTOR complex 1 (mTORC1) is composed of mTOR, G L, PRAS40, deptor, and raptor and regulates cell growth, whereas the complex 2 (mTORC2) consists of mTOR, G L, protor-1, mSIN1, deptor, and rictor and controls cytoskeleton regulation and cell survival (1,2).”
Background
Research works printed but not linked: 1
- Hamada, Upregulation of the mTOR complex 1 pathway by Rheb in pancreatic β cells leads to increased β cell mass and prevention of hyperglycemia, Diabetes
Cited by
Items 101–200 of 463
mTORC1 signaling in energy balance and metabolic disease
Catania, C., Binder, E., & Cota, D. (2010) · International Journal of Obesity · doi:10.1038/ijo.2010.208 · Cited by 76
van Vliet, E. A., Otte, W. M., Wadman, W. J., Aronica, E., Kooij, G., de Vries, H. E., Dijkhuizen, R. M., & Gorter, J. A. (2016) · Epilepsia · doi:10.1111/epi.13246 · Cited by 65
“Effects on growth have also been reported in mice,(20) and are not unexpected, considering the known role of RAP on cell size and growth via S6K1 and 4EBP1/eIF4E,(26) lipid metabolism, and the reduction of adipose tissue.(27) The extent of brain growth reduction, which can even cause parts of the brain to shrink, appe…”
BackgroundBelforte, N., Agostinone, J., Alarcon-Martinez, L., Villafranca-Baughman, D., Dotigny, F., Cueva Vargas, J. L., & Di Polo, A. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00466-z · Cited by 67
mTOR controls ChREBP transcriptional activity and pancreatic β cell survival under diabetic stress
Chau, G. C., Im, D. U., Kang, T. M., Bae, J. M., Kim, W., Pyo, S., Moon, E.-Y., & Um, S. H. (2017) · Journal of Cell Biology · doi:10.1083/jcb.201701085 · Cited by 67
“The individual roles of downstream effectors and components of mTORC1 and mTORC2 in β cells have been determined through analysis of mice lacking S6K1, Akt, rictor, and TSC1/2 or through analysis of mice treated with rapamycin (Pende et al., 2000; Bernal-Mizrachi et al., 2004; Mori et al., 2009; Houde et al., 2010; Gu…”
BackgroundMakki, K., Taront, S., Molendi-Coste, O., Bouchaert, E., Neve, B., Eury, E., Lobbens, S., Labalette, M., Duez, H., Staels, B., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092684 · Cited by 65
“Several previous studies on the metabolic effect of chronic rapamycin injection were controversial depending on the animal model (rat versus mouse), animal strain, diet, and age as well as rapamycin dose, route and frequency of administration [17,59,60].”
BackgroundRapamycin Increases Mortality in db/db Mice, a Mouse Model of Type 2 Diabetes
Sataranatarajan, K., Ikeno, Y., Bokov, A., Feliers, D., Yalamanchili, H., Lee, H. J., Mariappan, M. M., Tabatabai-Mir, H., Diaz, V., Prasad, S., et al. (2016) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glv170 · Cited by 65
“The toxicity of rapamycin in the db/db mice was not totally unexpected because chronic rapamycin treatment has been shown to result in insulin resistance in mice (10,26) and rats (51).”
BackgroundRangel, É. B. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.964205 · Cited by 66
“The mTOR complex 1 (mTORC1) is composed of mTOR, GbL, PRAS40, deptor and raptor and regulates cell growth, whereas the complex 2 (mTORC2) consists of mTOR, GbL, protor-1, mSIN1, deptor and rictor and controls cytoskeleton regulation and cell survival. mTORC1 activates cellular processes by phosphorylating two downstre…”
BackgroundInfluentialHonda, Y., Araki, Y., Hata, T., Ichihara, K., Ito, M., Tanaka, M., & Honda, S. (2015) · Journal of Aging Research · doi:10.1155/2015/425261 · Cited by 72
Dominick, G., Bowman, J., Li, X., Miller, R. A., & Garcia, G. G. (2017) · Aging Cell · doi:10.1111/acel.12525 · Cited by 62
“In vivo rapamycin treatments were performed with a single intraperitoneal injection of rapamycin at 5 mg kg 1 to each UM-HET mouse (ranging from 10 to 12 months of age) as previously described (Houde et al., 2010).”
MethodAgephagy – Adapting Autophagy for Health During Aging
Stead, E. R., Castillo-Quan, J. I., Martinez-Miguel, V. E., Lujan, C., Ketteler, R., Kinghorn, K. J., & Bjedov, I. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00308 · Cited by 62
Dai, W., Panserat, S., Mennigen, J. A., Terrier, F., Dias, K., Seiliez, I., & Cassy, S. (2013) · Journal of Experimental Biology · doi:10.1242/jeb.091157 · Cited by 85
“In vivo, most studies have focused on the chronic effects of rapamycin administration in mammals (Fang et al., 2013; Houde et al., 2010; Lamming et al., 2012; Sarbassov et al., 2006; Yang et al., 2012).”
BackgroundInfluentialDiacerhein Improves Glucose Tolerance and Insulin Sensitivity in Mice on a High-Fat Diet
Tobar, N., Oliveira, A. G., Guadagnini, D., Bagarolli, R. A., Rocha, G. Z., Araújo, T. G., Santos-Silva, J. C., Zollner, R. D. L., Boechat, L. H. B., Carvalheira, J. B. C., et al. (2011) · Endocrinology · doi:10.1210/en.2011-0249 · Cited by 63
Mammalian target of rapamycin and the kidney. II. Pathophysiology and therapeutic implications
Lieberthal, W., & Levine, J. S. (2012) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00015.2012 · Cited by 57
“Consistent with these notions, hyperlipidemia, characterized by increases in both LDL cholesterol and triglycerides, is a well-recognized side effect of chronic rapamycin administration and has been attributed to impaired deposition of lipids in adipose tissue and to increased hepatic synthesis of triglycerides (67, 1…”
BackgroundShum, M., Bellmann, K., St‐Pierre, P., & Marette, A. (2016) · Diabetologia · doi:10.1007/s00125-015-3839-6 · Cited by 64
“Western analysesWestern blots were performed as described [19].”
BackgroundMethodResultSelf-citationFernández‐Veledo, S., Vázquez‐Carballo, A., Vila‐Bedmar, R., Ceperuelo‐Mallafré, V., & Vendrell, J. J. (2013) · IUBMB Life · doi:10.1002/iub.1170 · Cited by 62
“Accordingly, chronic pharmacological inhibition of the mTORC1 signaling pathway is associated with a reduction in adipose tissue mass owing to both reduced adipocyte size and number (61).”
BackgroundKuo, H.-T., Lin, T.-H., Chen, W.-L., & Lee, H.-M. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.07.028 · Cited by 63
Szymanowski, M., Estebanez, M. S., Padidela, R., Han, B., Mosinska, K., Stevens, A., Damaj, L., Bars, F. P.-L., Lascouts, E., Reynaud, R., et al. (2016) · Journal of Clinical Endocrinology and Metabolism · doi:10.1210/jc.2016-2711 · Cited by 57
Allen, L., Ramalingam, L., Menikdiwela, K. R., Scoggin, S. O., Shen, C., Tomison, M. D., Kaur, G., Dufour, J. M., Chung, E., Kalupahana, N. S., et al. (2017) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2017.07.003 · Cited by 59
Li, H., Zhou, B., Xu, L., Liu, J., Zang, W., Wu, S., & Sun, H. (2014) · Endocrinology · doi:10.1210/en.2014-1058 · Cited by 56
Rapamycin Impairs Proliferation of Transplanted Islet β Cells
Niclauß, N., Bosco, D., Morel, P., Giovannoni, L., Berney, T., & Parnaud, G. (2011) · Transplantation · doi:10.1097/tp.0b013e31820c10c8 · Cited by 54
“Impairment of islet function in vivo induced by rapamycin was previously observed in normal rats (22, 23).”
BackgroundGrowth factor, energy and nutrient sensing signalling pathways in metabolic ageing
Bettedi, L., & Foukas, L. C. (2017) · Biogerontology · doi:10.1007/s10522-017-9724-6 · Cited by 53
“In fact, rapamycin increases lipolysis in the adipose tissue in rats, causing pronounced hyperlipidemia (Houde et al. 2010).”
BackgroundResults of a phase II study of sirolimus and cyclophosphamide in patients with advanced sarcoma
Schuetze, S. M., Zhao, L., Chugh, R. K., Thomas, D. G., Lucas, D. R., Metko, G., Zalupski, M. M., & Baker, L. H. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.03.022 · Cited by 53
Lashinger, L. M., Malone, L. M., Brown, G. W., Daniels, E. A., Goldberg, J. A., Otto, G. M., Fischer, S. M., & Hursting, S. D. (2011) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0023 · Cited by 53
“Moreover, chronic rapamycin treatment stimulates hepatic gluconeogenesis (40), which could further disrupt glucose homeostasis.”
BackgroundLiu, H., Liu, R., Xiong, Y., Li, X. O., Wang, X., Ma, Y., Guo, H., Hao, L., Yao, P., Liu, L., et al. (2014) · Amino Acids · doi:10.1007/s00726-014-1752-9 · Cited by 53
“…application of rapamycin, an inhibitor of mTORC1 in the clinic as an effective immunosuppressant, was found to promote glucose intolerance and a diabetes-like syndrome (Sipula et al. 2006; Houde et al. 2010), implicating that a certain degree of mTORC1 activity is required for insulin signaling.”
BackgroundStaying young at heart: autophagy and adaptation to cardiac aging
Leon, L. J., & Gustafsson, Å. B. (2015) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2015.11.006 · Cited by 55
Jeong, M., Park, J., Youn, D., Jung, Y., Kang, J., Lim, S., Kang, M.-W., Kim, H., So, H., Park, R., et al. (2017) · Metabolism · doi:10.1016/j.metabol.2017.05.009 · Cited by 55
mTOR is a Key Protein Involved in the Metabolic Effects of Simple Sugars
Sangüesa, G., Roglans, N., Baena, M., Velázquez, A. M., Laguna, J. C., & Alegret, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20051117 · Cited by 56
“Abbreviations 4EBP eIF4E binding protein AMPK activating transcription factor 6 ATF6 adenosine monophosphate-activated protein kinase CRTC2 CREB-regulated transcription coactivator 2 DEPTOR DEP domain-containing mTOR-interacting protein ER endoplasmic reticulum FoxO1 forkhead box protein O1 G6Pase glucose 6-phosphatas…”
BackgroundInfluentialRoss, C., Salmon, A., Strong, R., Fernandez, E., Javors, M., Richardson, A., & Tardif, S. (2015) · Aging · doi:10.18632/aging.100843 · Cited by 51
“Reports regarding rapamycin’s effects on lipid utilization in vivo in rodents are similarly inconsistent; rapamycin has been reported to decrease, increase or not effect fat accumulation among several different studies [1, 11, 37, 38, 49, 50].”
Nutrient sensing pathways as therapeutic targets for healthy ageing
Aiello, A., Accardi, G., Candore, G., Gambino, C. M., Mirisola, M., Taormina, G., Virruso, C., & Caruso, C. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1294684 · Cited by 52
Sun, Q., Lin, G., Li, L., Jin, X.-T., Huang, L., Zhang, G., Yang, W. M., Chen, K., Xiang, R., Chen, C., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00665 · Cited by 57
Yan, X., Huang, S., Yang, Y., Lu, Z., Li, F., Jiang, L., Jiang, Y., & Liu, J. (2021) · Liver Transplantation · doi:10.1002/lt.26387 · Cited by 55
(2020) · International Review of Neurobiology · doi:10.1016/bs.irn.2020.03.018 · Cited by 50
Fairaq, A., Shawky, N. M., Osman, I., Pichavaram, P., & Segar, L. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.02.016 · Cited by 51
mTOR: A double-edged sword for diabetes
Tuo, Y., & Xiang, M. (2018) · Journal of Leukocyte Biology · doi:10.1002/jlb.3mr0317-095rr · Cited by 53
Kang, S. A., O’Neill, D. J., Machl, A. W., Lumpkin, C. J., Galda, S. N., Sengupta, S., Mahoney, S. J., Howell, J. J., Molz, L., Hahm, S., et al. (2019) · Cell chemical biology · doi:10.1016/j.chembiol.2019.05.009 · Cited by 52
Limitations of IL-2 and Rapamycin in Immunotherapy of Type 1 Diabetes
Baeyens, A., Pérol, L., Fourcade, G., Cagnard, N., Carpentier, W., Woytschak, J., Boyman, O., Hartemann, A., & Piaggio, E. (2013) · Diabetes · doi:10.2337/db13-0214 · Cited by 49
“Furthermore, in rodents, long-term RAPA treatment severely impairs glucose tolerance, affecting hepatic gluconeogenesis (41,42), adipocyte lipid uptake (41), skeletal muscle insulin sensitivity (43), and b-cell homeostasis (41).”
BackgroundResultGlycemic control in patients with insulinoma
Matej, A., Bujwid, H., & Wroński, J. (2016) · HORMONES · doi:10.14310/horm.2002.1706 · Cited by 55
Jahrling, J. B., Lin, A.-L., DeRosa, N., Hussong, S. A., Van Skike, C. E., Girotti, M., Javors, M., Zhao, Q., Maslin, L. A., Asmis, R., et al. (2018) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x17705973 · Cited by 50
Therapeutic Use of mTOR Inhibitors in Renal Diseases: Advances, Drawbacks, and Challenges
Viana, S. D., Reis, F., & Alves, R. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/3693625 · Cited by 48
“Activation of mTOR complexes 1 and 2 promotes fat deposition in the adipose tissue [138, 139], which is in agreement with the rapamycininduced hyperlipidemia seen clinical practice [140].”
BackgroundmTOR activation protects liver from ischemia/reperfusion‐induced injury through NF‐κB pathway
Li, Z., Zhang, J., Mulholland, M. T., & Zhang, W. (2017) · The FASEB Journal · doi:10.1096/fj.201601278r · Cited by 48
Magdalon, J., Chimin, P., Belchior, T., das Neves, R. X., Vieira‐Lara, M. A., Andrade, M. L., Farias, T. S. M., Lopes, A. B., Paschoal, V. A., Yamashita, A. S., et al. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2016.02.023 · Cited by 48
Self-citationPPARγ activation attenuates glucose intolerance induced by mTOR inhibition with rapamycin in rats
Festuccia, W. T., Blanchard, P.-G., Belchior, T., Chimin, P., Paschoal, V. A., Magdalon, J., Hirabara, S. M., Simões, D., St-Pierre, P., Carpinelli, A., et al. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00683.2013 · Cited by 46
Self-citationPhysiological and Pathological Role of mTOR Signaling in Astrocytes
Hochmuth, L., & Hirrlinger, J. (2024) · Neurochemical Research · doi:10.1007/s11064-024-04306-6 · Cited by 228
“Chronic mTORC1 inhibition by rapamycin, as well as the disruption of mTORC2 in various tissues, leads to insulin resistance [3, 44–46].”
Manipulation of health span and function by dietary caloric restriction mimetics
Roth, G. S., & Ingram, D. K. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12834 · Cited by 46
Paschoal, V. A., Amano, M. T., Belchior, T., Magdalon, J., Chimin, P., Andrade, M. L., Ortiz‐Silva, M., Castro, É., Yamashita, A. S., Neto, J. C. R., et al. (2016) · Immunobiology · doi:10.1016/j.imbio.2016.09.014 · Cited by 48
Self-citationmTOR Inhibition Role in Cellular Mechanisms
Zaza, G., Granata, S., Caletti, C., Signorini, L. F., Stallone, G., & Lupo, A. (2018) · Transplantation · doi:10.1097/tp.0000000000001806 · Cited by 48
Dai, W., Panserat, S., Terrier, F., Seiliez, I., & Cassy, S. (2014) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00166.2014 · Cited by 48
Gkioni, L., Nespital, T., Baghdadi, M., Monzó, C., Bali, J., Nassr, T., Cremer, A. L., Beyer, A., Deelen, J., Backes, H., et al. (2025) · Nature Aging · doi:10.1038/s43587-025-00876-4 · Cited by 52
Fuhrmann, A., Lopes, P., Sereno, J., Pedro, J., Espinoza, D., Pereira, M. J., Reis, F., Eriksson, J. W., & Carvalho, E. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.01.020 · Cited by 49
“Hyperlipidemia, potentially resulting from increased adipose tissue lipolysis or hepatic TG synthesis, has been suggested to represent one of the factors contributing to peripheral insulin resistance following systemic mTOR inhibition, as previously indicated [25,27,28].”
BackgroundResultCarter, C. S., Marzetti, E., Leeuwenburgh, C., Manini, T., Foster, T. C., Groban, L., Scarpace, P. J., & Morgan, D. (2012) · The Journals of Gerontology: Series A · doi:10.1093/gerona/glr042 · Cited by 44
Leontieva, O. V., Paszkiewicz, G., Demidenko, Z. N., & Blagosklonny, M. V. (2013) · Cell Death & Disease · doi:10.1038/cddis.2012.202 · Cited by 44
Dietary restriction and the pursuit of effective mimetics
Selman, C. (2014) · Proceedings of The Nutrition Society · doi:10.1017/s0029665113003832 · Cited by 51
Liu, R., Li, H., Fan, W., Qiu, J. F., Tingting, C., Wu, Y., Huang, J., Hao, L., & Yang, X. (2017) · Nutrients · doi:10.3390/nu9060565 · Cited by 46
“However, several previous studies, including a study conducted in our laboratory, have indicated that BCAA–associated mTORC1 activation is not required or sufficient to elicit insulin resistance [12,13].”
ResultThe Geroscience Hypothesis: Is It Possible to Change the Rate of Aging?
Austad, S. N. (2016) · Advances in Geroscience · doi:10.1007/978-3-319-23246-1_1 · Cited by 43
A natural product solution to aging and aging-associated diseases
Yang, C., Zhang, W., Dong, X., Fu, C., Yuan, J., Xu, M., Liang, Z. C., Qiu, C., & Xu, C. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107673 · Cited by 45
Autophagy in Hepatic Steatosis: A Structured Review
Ramos, V. D. M., Kowaltowski, A. J., & Kakimoto, P. A. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.657389 · Cited by 47
Impact of mTOR-I on fertility and pregnancy: state of the art and review of the literature
Framarino‐dei‐Malatesta, M., Derme, M., Manzia, T. M., Iaria, G., Luca, L. D., Fazzolari, L., Napoli, A., Berloco, P. B., Patel, T. H., Orlando, G., et al. (2013) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2013.824243 · Cited by 45
Alterations to mTORC1 signaling in the skeletal muscle differentially affect whole-body metabolism
Guridi, M., Kupr, B., Romanino, K., Lin, S., Falcetta, D., Tintignac, L. A. J., & Rüegg, M. A. (2016) · Skeletal Muscle · doi:10.1186/s13395-016-0084-8 · Cited by 48
“Paradoxically, prolonged treatment with rapamycin causes glucose intolerance and insulin resistance [10, 13, 16], which has been interpreted to be the result of the inactivation of mTORC2 [20].”
BackgroundGhrelin contributes to derangements of glucose metabolism induced by rapamycin in mice
Xu, G., Wang, Z., Li, Y., Li, Z., Tang, H. W., Zhao, J., Xiang, X., Ding, L., Ma, L., Yuan, F., et al. (2012) · Diabetologia · doi:10.1007/s00125-012-2509-1 · Cited by 42
Koschei the immortal and anti-aging drugs
Blagosklonny, M. V. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.520 · Cited by 42
“Also, chronic (everyday) treatment with rapamycin reduces adiposity and body weight.(6,7) (In some strains, chronic daily treatment was associated with insulin resistance (IR), but more on that latter).”
BackgroundResultLombardi, A., Gambardella, J., Du, X.-L., Sorriento, D., Mauro, M., Iaccarino, G., Trimarco, B., & Santulli, G. (2017) · Scientific Reports · doi:10.1038/s41598-017-15283-y · Cited by 43
Rapamycin and Dietary Restriction Induce Metabolically Distinctive Changes in Mouse Liver
Yu, Z., Wang, R., Fok, W. C., Coles, A., Salmon, A. B., & Pérez, V. (2014) · The Journals of Gerontology Series A · doi:10.1093/gerona/glu053 · Cited by 43
Adipose tissue ageing: implications for metabolic health and lifespan
Wang, G., Song, A., & Wang, Q. A. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01142-8 · Cited by 54
“Contra-dictory results on adiposity, adipose tissue inflammation and insulin resistance are obtained in rodents 219,220 .”
Paul, D. S., Grevengoed, T. J., Pascual, F. L., Ellis, J. M., Willis, M. S., & Coleman, R. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2014.03.001 · Cited by 45
“As previously reported in mice and humans [51], treatment with rapamycin for 10 weeks caused marked glucose intolerance to develop in the Acsl1H−/− mice.”
ResultmTORC1 in energy expenditure: consequences for obesity
Allard, C., Miralpeix, C., López-Gambero, A. J., & Cota, D. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00934-0 · Cited by 40
“For instance, chronic rapamycin treat-ment inhibits mTORC2 activity in adipose tissue and muscle, but not in liver 39,40 .”
Chronic rapamycin treatment causes diabetes in male mice
Schindler, C. E., Partap, U., Patchen, B., & Swoap, S. J. (2014) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00123.2014 · Cited by 42
Weiss, R., Fernandez, E., Liu, Y., Strong, R., & Salmon, A. B. (2018) · Aging · doi:10.18632/aging.101401 · Cited by 36
mTOR signaling in Brown and Beige adipocytes: implications for thermogenesis and obesity
Ye, Y., Liu, H., Zhang, F., & Hu, F. (2019) · Nutrition & Metabolism · doi:10.1186/s12986-019-0404-1 · Cited by 41
“The effects of rapamycin on metabolism depend on the length of treatment: 2–6 weeks of rapamycin treatment produce detrimental metabolic changes that are usually associated with insulin resistance, hyperlipidemia and glucose intolerance [76, 77], whereas prolonged (20 weeks) rapamycin treatment causes better metabolic…”
BackgroundDietary protein deprivation upregulates insulin signaling and inhibits gluconeogenesis in rat liver
Toyoshima, Y., Tokita, R., Ohne, Y., Hakuno, F., Noguchi, T., Minami, S., Kato, H., & Takahashi, S. (2010) · Journal of Molecular Endocrinology · doi:10.1677/jme-10-0102 · Cited by 43
Novel cancer therapies and their association with diabetes
Shariff, A. I., Syed, S. H., Shelby, R. A., Force, J. M., Clarke, J. M., D’Alessio, D. A., & Corsino, L. (2018) · Journal of Molecular Endocrinology · doi:10.1530/jme-18-0002 · Cited by 43
Rapamycin for longevity: the pros, the cons, and future perspectives
Roark, K. M., & Iffland, P. H. (2025) · Frontiers in Aging · doi:10.3389/fragi.2025.1628187 · Cited by 33
Bulterijs, S. (2011) · Rejuvenation Research · doi:10.1089/rej.2011.1153 · Cited by 39
Oridonin inhibits mTOR signaling and the growth of lung cancer tumors
Wang, Y., Lv, Y.-F., Lu, L., & Cai, L. (2014) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000154 · Cited by 37
Duval, A. P., Jeanneret, C., Santoro, T., & Dormond, O. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082225 · Cited by 40
“Similarly, rapamycin treated mice accumulate less adipose tissue [123,124].”
BackgroundE‐cigarettes damage the liver and alter nutrient metabolism in pregnant mice and their offspring
Li, G., Chan, Y. L., Wang, B., Saad, S., George, J., Oliver, B. G. G., & Chen, H. (2020) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14411 · Cited by 37
Single Rapamycin Administration Induces Prolonged Downward Shift in Defended Body Weight in Rats
Hebert, M. A., Licursi, M., Jensen, B., Baker, A., Milway, S. J., Malsbury, C. W., Grant, V. L., Adamec, R. E., Hirasawa, M., & Blundell, J. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093691 · Cited by 38
“Therefore, a single RAP injection does not appear to influence glucose homeostasis long-term, unlike the glucose tolerance that develops with daily administrations of RAP over a 2-week period, as shown previously [6,15,16,17].”
BackgroundMethodNuclear Receptors Reverse McGarry's Vicious Cycle to Insulin Resistance
Moore, D. D. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.03.016 · Cited by 39
mTORC1 pathway mediates beta cell compensatory proliferation in 60 % partial-pancreatectomy mice
Li, W., Zhang, H., Nie, A., Ni, Q., Li, F., Ning, G., Li, X., Gu, Y., & Wang, Q. (2016) · Endocrine · doi:10.1007/s12020-016-0861-5 · Cited by 37
“Moreover, the long-term effect of rapamycin on insulin sensitivity in peripheral tissue [26, 28, 29] made it difficult to dissect whether the outcome of decompensation is mainly due to loss of functional beta cell mass or induction of peripheral insulin resistance.”
BackgroundNeedham, E. J., Hingst, J. R., Onslev, J., Díaz‐Vegas, A., Leandersson, M. R., Huckstep, H., Kristensen, J. M., Kido, K., Richter, E. A., Højlund, K., et al. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.10.020 · Cited by 44
Nutrition, metabolism, and targeting aging in nonhuman primates
Balasubramanian, P., Mattison, J. A., & Anderson, R. M. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.02.002 · Cited by 49
(2013) · PubMed · Cited by 36
Geuna, E., Roda, D., Rafii, S., Jiménez, B., Capelán, M., Rihawi, K., Montemurro, F., Yap, T. A., Kaye, S. B., Bono, J. S. D., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.373 · Cited by 39
“…mechanisms provide a comprehensive explanation for the observation that inhibition of PI3K–AKT–mTOR pathway can lead to abrogated insulin function, impaired insulin secretion and development of insulin resistance (Crouthamel et al, 2009; Houde et al, 2010; Lamming et al, 2012; Fang et al, 2013).”
BackgroundRegulation of Adipocyte and Macrophage Functions by mTORC1 and 2 in Metabolic Diseases
Festuccia, W. T. (2020) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201900768 · Cited by 37
Self-citationWei, Z., Zhuang, Y., Liu, X., Zou, D., Mai, K., Sun, Z., & Ye, C. (2022) · Aquaculture · doi:10.1016/j.aquaculture.2022.739060 · Cited by 37
Map4k4 suppresses Srebp-1 and adipocyte lipogenesis independent of JNK signaling
Danai, L. V., Guilherme, A., Guntur, K., Straubhaar, J., Nicoloro, S. M. C., & Czech, M. (2013) · Journal of Lipid Research · doi:10.1194/jlr.m038802 · Cited by 36
de Almeida, A. A., da Silva, S. G., Lopim, G., Campos, D. V., Fernandes, J., Cabral, F., & Arida, R. (2018) · Journal of Neuroscience Research · doi:10.1002/jnr.24196 · Cited by 31
Xiao, P., Xie, Z., Kuang, Y., Liu, S., Zeng, C., Li, P., & Liu, E. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.03.031 · Cited by 34
Reifsnyder, P. C., Flurkey, K., Doty, R. A., Calcutt, N. A., Koza, R. A., & Harrison, D. E. (2022) · Aging Cell · doi:10.1111/acel.13666 · Cited by 37
“However, it promotes hyperglycemia in roughly 15% of human patients (Barlow et al., 2013), presumably by promoting systemic and hepatic insulin resistance and diminishing pancreatic response to glucose (Houde et al., 2010; Lamming et al., 2012; Schindler et al., 2014; Yang et al., 2012).”
BackgroundREDD1 promotes obesity-induced metabolic dysfunction via atypical NF-κB activation
Lee, D., Kim, T., Byeon, J., Park, M., Kim, S., Kim, J., Choi, S., Lee, G., Park, C., Lee, K. W., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34110-1 · Cited by 35
den Hartigh, L. J., Goodspeed, L., Wang, S. A., Kenerson, H. L., Omer, M., O’Brien, K. D., Ladiges, W., Yeung, R. S. W., & Subramanian, S. (2018) · Experimental Physiology · doi:10.1113/ep087207 · Cited by 34
“…that rapamycin administration leads to the development of hyperglycaemia, increased insulin levels and glucose intolerance (Aggarwal, Fernandez, & Soliman, 2006; Chang et al., 2009b; Cunningham et al., 2007; Fraenkel et al., 2008; Houde et al., 2010; Paschoal et al., 2017; Yang et al., 2012).”
Güemes, M., Dastamani, A., Ashworth, M. T., Morgan, K., Sian, E., Flanagan, S. E., Dattani, M., & Shah, P. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2018-00417 · Cited by 33
“The mechanisms by which sirolimus induces diabetogenic effects may include: (i) impaired b-cell proliferation by impairing AKT activation and signaling (IGF-1/mTOR/Akt pathway) [13]; (ii) direct b-cell toxicity; (iii) negativemodulation of insulin action in peripheral tissues including skeletal muscle, liver, and whit…”
BackgroundmTORC1 restrains adipocyte lipolysis to prevent systemic hyperlipidemia
Paolella, L. M., Mukherjee, S., Tran, C. M., Bellaver, B., Hugo, M., Luongo, T. S., Shewale, S. V., Lu, W., Chellappa, K., & Baur, J. A. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.12.003 · Cited by 34
Effect of Chronic Administration of Low Dose Rapamycin on Development and Immunity in Young Rats
Lu, Z.-Y., Liu, F.-R., Chen, L.-L., Zhang, H.-D., Ding, Y.-M., Liu, J.-X., Wong, M., & Zeng, L.-H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135256 · Cited by 27
Ramalingam, L., Oh, E., & Thurmond, D. C. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1176-1 · Cited by 37
“Moreover, adipocytes from T2D patients showed marked reductions in mTOR and S6 K proteins [239], correlating with recent evidence from human adipocytes whereby inhibition of mTOR/S6K1 resulted in impaired glucose uptake [240, 241].”
Anti-senescence therapies: a new concept to address cardiovascular disease
Stojanović, S. D., Thum, T., & Bauersachs, J. K. (2025) · Cardiovascular Research · doi:10.1093/cvr/cvaf030 · Cited by 34
“176,177”
Wu, L.-Y., Li, M., Qu, M., Li, X., Pi, L., Chen, Z., Zhou, S., Yi, X., Shi, X., Wu, J., et al. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.11.025 · Cited by 33
Kotha, S., Lawendy, B., Asim, S., Gomes, C., Yu, J., Orchanian‐Cheff, A., TOMLINSON, G. A., & Bhat, M. (2021) · World Journal of Transplantation · doi:10.5500/wjt.v11.i10.432 · Cited by 31
Rohrbach, S., Aslam, M., Niemann, B., & Schulz, R. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12650 · Cited by 38
“A major adverse effect of chronic rapamycin therapy is glucose intolerance and insulin resistance (Houde et al., 2010; Deblon et al., 2012), causing a condition known as ‘starvation-like diabetes’ (Lamming et al.”
BackgroundToyoshima, Y., Tokita, R., Taguchi, Y., Akanishi, N., Takenaka, A., Kato, H., Chida, K., Hakuno, F., Minami, S., & Takahashi, S. (2014) · Endocrine Journal · doi:10.1507/endocrj.ej13-0514 · Cited by 31
Rapamycin Normalizes Serum Leptin by Alleviating Obesity and Reducing Leptin Synthesis in Aged Rats
Scarpace, P. J., Matheny, M. E., Strehler, K. Y. E., Toklu, H. Z., Kirichenko, N., Carter, C. S., Morgan, D., & Tümer, N. (2015) · The Journals of Gerontology Series A · doi:10.1093/gerona/glu230 · Cited by 34
“Rapamycin also inhibited MTORC1/ P70 S6 signaling and well as the mTORC2 pathway (7).”
BackgroundMethodResultInfluential
Metadata
- Authors
- Houde, V. P., Brûlé, S., Festuccia, W. T., Blanchard, P.-G., Bellmann, K., Deshaies, Y., & Marette, A.
- Affiliations
- Institut universitaire de cardiologie et de pneumologie de Québec (CA)
- Corresponding author
- Marette, André
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2010-03-18
- Volume
- 59
- Issue
- 6
- Pages
- 1338-1348
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC2874694
- OpenAlex
- W2153442288
- Cited by
- 456
- References
- 51
- Citations by year
- 2026: 12 · 2025: 25 · 2024: 14 · 2023: 25 · 2022: 20 · 2021: 30 · 2020: 25 · 2019: 26 · 2018: 33 · 2017: 37 · 2016: 35 · 2015: 42 · 2014: 47 · 2013: 32 · 2012: 30
- FWCI
- 10.81
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval
- Canadian Institutes of Health Research (144336)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- hepatic gluconeogenesis, impaired glucose tolerance, hyperlipidemia, insulin resistance, PGC-1α, FOXO1, CRTC2, CREB, PI3K/Akt signaling, phosphoenolpyruvate carboxykinase, glucose-6-phosphatase, adiposity
- MeSH terms
- Adipose Tissue, Animals, Blood Glucose, C-Peptide, Fatty Acids, Nonesterified, Glucagon, Hyperlipidemias, Immunosuppressive Agents, Insulin, Liver, Male, Pyruvates, RNA, Triglycerides, Down-Regulation, Polymerase Chain Reaction, Rats, Sprague-Dawley, Adipocytes, Glucose Intolerance, Muscle, Skeletal, Sirolimus, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.